All people

Researcher · Executive

Feng Ren

FR

Chief Scientific Officer, Executive Director & Co-CEO at Insilico Medicine

Ren leads Insilico Medicine's drug research, turning molecules proposed by generative AI into laboratory and clinical programs. A medicinal chemist who previously led neuroscience discovery at GSK, he provides the experimental and development expertise needed to test whether AI-designed drugs work in the real world.

See something inaccurate or outdated?

Background

Current role
Chief Scientific Officer, Executive Director & Co-CEO 2021-present
Previously
2018-2021Senior Vice President and Head of Drug R&D Services,
2007-2018Principal Scientist / Program Leader / Director / Head of Chemistry, Neurodegeneration DPU,
About this data

Work and education history is primarily focused on AI-relevant roles and may not be comprehensive.

Last editorial review: August 8, 2026

News 1

person_addedFeng Ren added to the database

Insilico Medicine Chief Scientific Officer, leading AI-enabled drug-discovery research.

July 2, 2026

Citation Trend

1 snapshots
Citation snapshot on Jul 2, '263,605Jul 2, '26
3,605citations as of Jul 2, '26
For today’s citation count and citations per paper, visit Google Scholar.

You may also be interested in